Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

Recently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized non-small cell lung cancer (NSCLC) treatment. However, resistance remains a major obstacle. Anexelekto (AXL) is a member of receptor tyrosine kinases (RTKs) and shares the same downstream signaling...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yaqiong, Zhang, Zengli, Miao, Liyun, Yang, Zhimin, Yang, Jie, Wang, Yinhua, Qian, Danwen, Cai, Hourong, Wang, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838623/
https://www.ncbi.nlm.nih.gov/pubmed/27712586
http://dx.doi.org/10.3727/096504016X14648701447814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838623/
https://www.ncbi.nlm.nih.gov/pubmed/27712586
http://dx.doi.org/10.3727/096504016X14648701447814

Ejemplares similares